4 January 2024
Latham & Watkins Advises on Arrowhead Pharmaceuticals’ US$450 Million Underwritten Offering of Common Stock
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Bush Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Anthony Gostanian | Latham & Watkins LLP | Counsel | Not stated | Not stated |
| Peter Simon | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Brian Daley | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Sterling Swift | Latham & Watkins LLP | Associate | Not stated | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 450m (US$450.0 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Arrowhead Pharmaceuticals, Inc. (Issuer)